The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy
Abstract
Objectives To determine the expression of prostate-specific membrane antigen (PSMA) before and after androgen-deprivation therapy and to compare PSMA expression with prostate-specific antigen (PSA) expression. Methods We studied specimens from 20 patients with prostate cancer undergoing medical or surgical castration or combination androgen-deprivation therapy in whom matched pretreatment and post-treatment tissue specimens were available and 16 patients in whom only a post-treatment specimen was available. The expression of PSMA and PSA in the tissue specimens was determined by immunoperoxidase staining. The extent of staining was calculated by multiplying the percent of antigen-positive tumor cells by the staining intensity to arrive at a stain index for each biomarker. An in vitro study assessed the concentration of PSMA and PSA in extracts of LNCaP cells cultured in the presence or absence of androgen as determined by immunoassays and Western blot analysis. Results PSMA reactivity was found to be increased in 55% (11 of 20) of post-treatment primary tissues and 100% (4 of 4) of post-treatment metastatic specimens. In contrast, PSA expression was found to be decreased in 70% (14 of 20) of post-treatment primary and 100% (4 of 4) of post-treatment metastatic specimens. Neither type of androgen-deprivation treatment nor tissue sensitivity to androgen deprivation appeared to influence degree of biomarker expression. PSMA was found to be downregulated and PSA upregulated when…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PSMA is a transmembrane protein found predominantly in prostate cells, and its expression increases as prostate malignancy progresses67,68.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [67]
In the citing paper
“In particular, PSMA expression increases following ADT—the cornerstone of prostate cancer treatment—making PSMA a prominent target for the treatment of CRPC67.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [67]
Citations
Cites
McDonnell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C. J., Chung, L. W. K., Hsieh, J., Tu, S., & Campbell, M. L. (1992) · PubMed · Cited by 1,049
Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line
Miyashita, T., & Reed, J. (1993) · Blood · doi:10.1182/blood.v81.1.151.151 · Cited by 882
Stamey, T. A., Freiha, F. S., McNeal, J. E., Redwine, E. A., Whittemore, A. S., & Schmid, H.-P. (1993) · Cancer · doi:10.1002/1097-0142(19930201)71:3+<933::aid-cncr2820711408>3.0.co;2-l · Cited by 799
Thalmann, G. N., Anezinis, P., Chang, S., Zhau, H. E., Kim, E. E., Hopwood, V. L., Pathak, S., von Eschenbach, A. C., & Chung, L. W. K. (1994) · PubMed · Cited by 727
Activation of Programmed Cell Death in the Rat Ventral Prostate after Castration*
KYPRIANOU, N., & ISAACS, J. T. (1988) · Endocrinology · doi:10.1210/endo-122-2-552 · Cited by 720
Hanchette, C. L., & Schwartz, G. G. (1992) · Cancer · doi:10.1002/1097-0142(19921215)70:12<2861::aid-cncr2820701224>3.0.co;2-g · Cited by 645
Expression of the prostate-specific membrane antigen.
Israeli, R., Powell, C. T., Corr, J., Fair, W. R., & Heston, W. D. W. (1994) · PubMed · Cited by 601
Colombel, M. C., Symmans, W. F., de Medina, S. G. D., O’Toole, K., Chopin, D. K., Benson, M. C., Olsson, C. A., Korsmeyer, S. J., & Buttyan, R. (1993) · PubMed · Cited by 591
Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues
Wright, G. L., Haley, C., Beckett, M. L., & Schellhammer, P. F. (1995) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/1078-1439(95)00002-y · Cited by 591
Self-citationThe Promoter of the Prostate-Specific Antigen Gene Contains a Functional Androgen Responsive Element
Riegman, P. H. J., Vlietstra, R. J., van der Korput, J. A. G. M., Brinkmann, A. O., & Trapman, J. (1991) · Molecular Endocrinology · doi:10.1210/mend-5-12-1921 · Cited by 451
Research works printed but not linked: 2
- Horoszewicz, 1987, Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients, Anticancer Res, 7, 927
- Kantoff, 1993, Advances in nonsurgical management of prostate cancer, Adv Oncol, 9, 24
Cited by
Dhar, S., Gu, F. X., Langer, R., Farokhzad, O. C., & Lippard, S. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809154105 · Cited by 994
Afshar-Oromieh, A., Avtzi, E., Giesel, F. L., Holland-Letz, T., Linhart, H. G., Eder, M., Eisenhut, M., Boxler, S., Hadaschik, B. A., Kratochwil, C., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2949-6 · Cited by 964
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
Ghosh, A., & Heston, W. D. W. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10661 · Cited by 878
Chang, S. S., Reuter, V. E., Heston, W. D. W., Bander, N. H., Grauer, L. S., & Gaudin, P. B. (1999) · PubMed · Cited by 825
Bostwick, D. G., Pacelli, A., Blute, M., Roche, P., & Murphy, G. P. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980601)82:11<2256::aid-cncr22>3.0.co;2-s · Cited by 698
Metadata
- Authors
- Wright, G. L., Mayer Grob, B., Haley, C., Grossman, K., Newhall, K., Petrylak, D., Troyer, J., Konchuba, A., Schellhammer, P. F., & Moriarty, R.
- Affiliations
- Eastern Virginia Medical School (US)
- Corresponding author
- Wright, George L.
- ORCID
- Petrylak, Daniel
- Venue
- Urology
- Publisher
- Elsevier BV
- Published
- 1996-08
- Volume
- 48
- Issue
- 2
- Pages
- 326-334
- ISSN
- 0090-4295 (ISSN-L)
- OpenAlex
- W2016973566
- Cited by
- 635
- References
- 36
- Citations by year
- 2026: 14 · 2025: 14 · 2024: 20 · 2023: 22 · 2022: 25 · 2021: 38 · 2020: 18 · 2019: 34 · 2018: 37 · 2017: 44 · 2016: 34 · 2015: 30 · 2014: 21 · 2013: 21 · 2012: 24
- FWCI
- 10.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Urology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Keywords
- prostate-specific membrane antigen, androgen deprivation therapy, prostate cancer, prostate-specific antigen, castration, LNCaP cells, androgen receptor, metastatic prostate cancer, castration-resistant prostate cancer, biomarker expression
- MeSH terms
- Androgen Antagonists, Antigens, Neoplasm, Antigens, Surface, Dipeptidases, Humans, Male, Orchiectomy, Prostatic Neoplasms, Tumor Cells, Cultured, Up-Regulation, Prostate-Specific Antigen, Glutamate Carboxypeptidase II, Culture Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. https://app.cochat.ai/papers/10.1016/s0090-4295(96)00184-7
- The paper
- Wright, G. L., Mayer Grob, B., Haley, C., Grossman, K., Newhall, K., Petrylak, D., Troyer, J., Konchuba, A., Schellhammer, P. F., & Moriarty, R. (1996). Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. https://doi.org/10.1016/s0090-4295(96)00184-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.